Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

Barliz Waissengrin, Abed Agbarya, Esraa Safadi, Hagit Padova, Ido Wolf

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)581-583
Number of pages3
JournalThe Lancet Oncology
Issue number5
StatePublished - May 2021

Cite this